Taysha Gene Therapies (TSHA) Operating Income (2022 - 2025)
Historic Operating Income for Taysha Gene Therapies (TSHA) over the last 4 years, with Q3 2025 value amounting to -$34.0 million.
- Taysha Gene Therapies' Operating Income fell 3137.69% to -$34.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$102.1 million, marking a year-over-year decrease of 1635.7%. This contributed to the annual value of -$91.5 million for FY2024, which is 2625.66% down from last year.
- Latest data reveals that Taysha Gene Therapies reported Operating Income of -$34.0 million as of Q3 2025, which was down 3137.69% from -$26.8 million recorded in Q2 2025.
- Over the past 5 years, Taysha Gene Therapies' Operating Income peaked at -$16.2 million during Q4 2023, and registered a low of -$54.0 million during Q4 2022.
- In the last 4 years, Taysha Gene Therapies' Operating Income had a median value of -$24.3 million in 2024 and averaged -$27.2 million.
- Its Operating Income has fluctuated over the past 5 years, first skyrocketed by 6989.59% in 2023, then crashed by 5937.23% in 2024.
- Quarter analysis of 4 years shows Taysha Gene Therapies' Operating Income stood at -$54.0 million in 2022, then skyrocketed by 69.9% to -$16.2 million in 2023, then decreased by 22.69% to -$19.9 million in 2024, then tumbled by 70.7% to -$34.0 million in 2025.
- Its Operating Income was -$34.0 million in Q3 2025, compared to -$26.8 million in Q2 2025 and -$21.4 million in Q1 2025.